Valuation Update With 7 Day Price Move • Jul 09
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥19.90, the stock trades at a trailing P/E ratio of 42.1x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total loss to shareholders of 18% over the past three years. Announcement • Jun 30
Enwei Pharmaceutical Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026 Enwei Pharmaceutical Co., Ltd. announced that they will report first half, 2026 results on Aug 27, 2026 Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥24.63, the stock trades at a trailing P/E ratio of 52.1x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total loss to shareholders of 6.2% over the past three years. Declared Dividend • May 25
Dividend of CN¥0.68 announced Shareholders will receive a dividend of CN¥0.68. Ex-date: 28th May 2026 Payment date: 28th May 2026 Dividend yield will be 3.9%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is not covered by earnings (146% earnings payout ratio) nor is it covered by cash flows (274% cash payout ratio). The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 63% to bring the payout ratio under control. However, EPS has declined by 19% over the last 5 years so the company would need to reverse this trend. Reported Earnings • Apr 27
Full year 2025 earnings released: EPS: CN¥0.51 (vs CN¥0.37 in FY 2024) Full year 2025 results: EPS: CN¥0.51 (up from CN¥0.37 in FY 2024). Revenue: CN¥900.8m (up 11% from FY 2024). Net income: CN¥51.9m (up 39% from FY 2024). Profit margin: 5.8% (up from 4.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • Apr 27
Enwei Pharmaceutical Co., Ltd., Annual General Meeting, May 18, 2026 Enwei Pharmaceutical Co., Ltd., Annual General Meeting, May 18, 2026, at 15:00 China Standard Time. Location: The Company's Meeting Room, Chengdu, Sichuan China Announcement • Mar 31
Enwei Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 27, 2026 Enwei Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 27, 2026 Announcement • Dec 31
Enwei Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 27, 2026 Enwei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 27, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: CN¥0.018 loss per share (vs CN¥0.041 profit in 3Q 2024) Third quarter 2025 results: CN¥0.018 loss per share (down from CN¥0.041 profit in 3Q 2024). Revenue: CN¥187.6m (up 9.0% from 3Q 2024). Net loss: CN¥1.76m (down 143% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Announcement • Sep 30
Enwei Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Enwei Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Board Change • Aug 29
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Ya Liu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jul 02
Enwei Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025 Enwei Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025 New Risk • Jun 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (5.5% net profit margin). Valuation Update With 7 Day Price Move • Jun 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥31.42, the stock trades at a trailing P/E ratio of 70x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 22% over the past year. Declared Dividend • May 23
Dividend of CN¥0.18 announced Shareholders will receive a dividend of CN¥0.18. Ex-date: 28th May 2025 Payment date: 28th May 2025 Dividend yield will be 0.7%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (35% cash payout ratio). The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 56% to shift the payout ratio to a potentially unsustainable range, which is more than the 16% EPS decline seen over the last 5 years. Announcement • Apr 22
Enwei Pharmaceutical Co., Ltd., Proposes Final Cash Dividend for 2024 Enwei Pharmaceutical Co., Ltd., on 21 April 2025, announced the profit distribution proposal for final cash dividend of CNY 1.80000000 per 10 share (tax included) for 2024. Reported Earnings • Apr 21
Full year 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.83 in FY 2023) Full year 2024 results: EPS: CN¥0.37 (down from CN¥0.83 in FY 2023). Revenue: CN¥812.1m (up 3.4% from FY 2023). Net income: CN¥37.5m (down 57% from FY 2023). Profit margin: 4.6% (down from 11% in FY 2023). The decrease in margin was driven by higher expenses. Announcement • Apr 21
Enwei Pharmaceutical Co., Ltd., Annual General Meeting, May 12, 2025 Enwei Pharmaceutical Co., Ltd., Annual General Meeting, May 12, 2025, at 15:00 China Standard Time. Location: The Company's Meeting Room, Chengdu, Sichuan China Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥27.08, the stock trades at a trailing P/E ratio of 76.4x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 11% over the past year. Announcement • Mar 31
Enwei Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 21, 2025 Enwei Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 21, 2025 Announcement • Dec 31
Enwei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 21, 2025 Enwei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 21, 2025 Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: CN¥0.041 (vs CN¥0.086 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.041 (down from CN¥0.086 in 3Q 2023). Revenue: CN¥172.2m (down 1.4% from 3Q 2023). Net income: CN¥4.09m (down 54% from 3Q 2023). Profit margin: 2.4% (down from 5.1% in 3Q 2023). Announcement • Sep 30
Enwei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Enwei Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥27.27, the stock trades at a trailing P/E ratio of 67.6x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 6.0% over the past year. New Risk • Sep 22
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 138% Paying a dividend despite having no free cash flows. Earnings have declined by 8.5% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.2% net profit margin). Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: CN¥0.095 (vs CN¥0.35 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.095 (down from CN¥0.35 in 2Q 2023). Revenue: CN¥204.7m (up 5.3% from 2Q 2023). Net income: CN¥9.51m (down 74% from 2Q 2023). Profit margin: 4.6% (down from 19% in 2Q 2023). The decrease in margin was driven by higher expenses. Announcement • Jun 29
Enwei Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Enwei Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Valuation Update With 7 Day Price Move • May 22
Investor sentiment deteriorates as stock falls 32% After last week's 32% share price decline to CN¥28.08, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total loss to shareholders of 31% over the past year. Declared Dividend • May 20
Dividend of CN¥0.80 announced Shareholders will receive a dividend of CN¥0.80. Ex-date: 23rd May 2024 Payment date: 23rd May 2024 Dividend yield will be 1.8%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (65% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. The company's earnings per share (EPS) would need to decline by 28% to shift the payout ratio to a potentially unsustainable range, which is more than the 10% EPS decline seen over the last 5 years. Announcement • Apr 23
Enwei Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024 Enwei Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024, at 15:00 China Standard Time. Location: The Company's Meeting Room, Chengdu, Sichuan China Reported Earnings • Apr 22
First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.40 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.40 in 1Q 2023). Revenue: CN¥183.5m (down 8.6% from 1Q 2023). Net income: CN¥8.42m (down 70% from 1Q 2023). Profit margin: 4.6% (down from 14% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Announcement • Mar 30
Enwei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024 Enwei Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024 Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥31.83, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 21% over the past year. Announcement • Jan 31
Enwei Pharmaceutical Co., Ltd. Approves Appointment of Independent Directors and Non-Employee Supervisors Enwei Pharmaceutical Co., Ltd. at its extraordinary general meeting held on 29 January 2024, approved the appointment of Liu Ya, Peng Gang, Li Chun as independent directors and Du Zhanghong, Yi Li as non-employee supervisors. Announcement • Dec 29
Enwei Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024 Enwei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024 New Risk • Nov 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 123% Cash payout ratio: 237% Earnings have declined by 1.2% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.20 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.20 in 3Q 2022). Revenue: CN¥174.6m (up 18% from 3Q 2022). Net income: CN¥8.97m (down 13% from 3Q 2022). Profit margin: 5.1% (down from 6.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Announcement • Oct 23
Enwei Pharmaceutical Co., Ltd. (SZSE:301331) announces an Equity Buyback for CNY 150 million worth of its shares. Enwei Pharmaceutical Co., Ltd. (SZSE:301331) announces a share repurchase program. Under the program, the company will repurchase up to CNY 150 million worth of its shares. The shares will be repurchased at a price not more than CNY 63.41 per share. The repurchased shares will be used for ESOP or equity incentives. The repurchase period will be not more than 12 months. Announcement • Sep 30
Enwei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023 Enwei Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 New Risk • Sep 08
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 114% Cash payout ratio: 287% Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Reported Earnings • Aug 28
Second quarter 2023 earnings released Second quarter 2023 results: EPS: CN¥0.52. Net income: CN¥36.3m (up CN¥36.3m from 2Q 2022). Valuation Update With 7 Day Price Move • Aug 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥46.99, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Announcement • May 17
Enwei Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 23 May 2023 Enwei Pharmaceutical Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 16.00000000 for the year 2022, payable on 23 May 2023. Record date is 22 May 2023. Ex-date is 23 May 2023. Valuation Update With 7 Day Price Move • Dec 13
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥52.01, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 39x in the Pharmaceuticals industry in China. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 09
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥52.85, the stock trades at a trailing P/E ratio of 43.3x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥40.35, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Board Change • Sep 21
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.